Ather­sys tries to post-hoc-an­a­lyze its way out of an­oth­er tri­al fail for stroke stem cell ther­a­py

Ather­sys’ stem cell ther­a­py has failed yet again.

In a 206-per­son tri­al con­duct­ed in Japan, Ather­sys’ stem cell ther­a­py for stroke failed its pri­ma­ry end­point of “ex­cel­lent out­come,” a com­bined mea­sure of three stroke re­cov­ery scores.

While a greater per­cent­age of pa­tients in the treat­ment group reached the pri­ma­ry end­point com­pared to place­bo, that dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER